| Court: | ded |
| Docket #: | 1:16-cv-00638 |
| Case Name: | Vectura Limited v. GlaxoSmithKline LLC et al |
| PACER case #: | 59932 |
| Date filed: | 2016-07-27 |
| Assigned to: | Judge Richard G. Andrews |
| Case Cause: | 35:271 Patent Infringement |
| Nature of Suit: | 830 Patent |
| Jury Demand: | Both |
| Jurisdiction: | Federal Question |
| Represented Party | Attorney & Contact Info |
| Vectura Limited Plaintiff |
Kelly E. Farnan Brendan M. O'Malley Christine Dealy Haynes Christopher P. Borello Damien N. Dombrowski Michael P. McGraw |
| GlaxoSmithKline LLC Defendant |
Jack B. Blumenfeld |
| Glaxo Group Limited Defendant |
Jack B. Blumenfeld |
| Date Filed | Document # | Attachment # | Short Description | Long Description | Upload date | SHA1 hash |
| 2016-07-27 | 1 | 0 | COMPLAINT for PATENT INFRINGEMENT filed with Jury Demand against Glaxo Group Limited, GlaxoSmithKline LLC - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1970202.) - filed by Vectura Limited. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(nmb) (Entered: 07/27/2016) | |||
| 2016-07-27 | 2 | 0 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmb) (Entered: 07/27/2016) | |||
| 2016-07-27 | 3 | 0 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,303,991. (nmb) (Entered: 07/27/2016) | |||
| 2016-07-27 | 4 | 0 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Vectura Group Investments Ltd., Corporate Parent Vectura Group plc, Corporate Parent HBM Healthcare Investments (Cayman) Ltd. for Vectura Limited filed by Vectura Limited. (nmb) (Entered: 07/27/2016) | |||
| 2016-08-12 | 5 | 0 | First AMENDED COMPLAINT For Patent Infringement against Glaxo Group Limited, GlaxoSmithKline LLC- filed by Vectura Limited.(Farnan, Kelly) Modified on 8/15/2016 (nms). (Entered: 08/12/2016) | |||
| 2016-08-12 | 6 | 0 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,435,567; . (Farnan, Kelly) (Entered: 08/12/2016) | |||
| 2016-10-11 | 7 | 0 | WAIVER OF SERVICE returned executed by Vectura Limited: For GlaxoSmithKline LLC waiver sent on 8/17/2016, answer due 10/17/2016. (Farnan, Kelly) Modified on 10/13/2016 (nms). (Entered: 10/11/2016) | |||
| 2016-10-11 | 8 | 0 | WAIVER OF SERVICE returned executed by Vectura Limited: For Glaxo Group Limited waiver sent on 8/17/2016, answer due 10/17/2016. (Farnan, Kelly) Modified on 10/13/2016 (nms). (Entered: 10/11/2016) | |||
| 2016-10-14 | 9 | 0 | MOTION for Pro Hac Vice Appearance of Attorney Christopher P. Borello and Brendan M. OMalley - filed by Vectura Limited. (Farnan, Kelly) (Entered: 10/14/2016) | |||
| 2016-10-17 | 10 | 0 | MOTION to Dismiss the Amended Complaint - filed by GlaxoSmithKline LLC. (Blumenfeld, Jack) Modified on 10/18/2016 (nms). (Entered: 10/17/2016) | |||
| 2016-10-17 | 11 | 0 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent GlaxoSmithKline plc. for GlaxoSmithKline LLC filed by GlaxoSmithKline LLC. (Blumenfeld, Jack) (Entered: 10/17/2016) | |||
| 2016-10-25 | 12 | 0 | STIPULATION TO EXTEND TIME for Plaintiff Vecture Limited to respond to Defendant GlaxoSmithKline's Motion to Dismiss the Amended Complaint AND the time for Defendant to file its Reply Brief to through and including November 10, 2016 and December 1, 2016, respectively - filed by Vectura Limited. (Farnan, Kelly) (Entered: 10/25/2016) | |||
| 2016-11-01 | 13 | 0 | MOTION for Pro Hac Vice Appearance of Attorney Damien Dombrowski - filed by Vectura Limited. (Farnan, Kelly) (Entered: 11/01/2016) | |||
| 2016-11-10 | 14 | 0 | Unopposed Motion For Leave to File a Second Amended Complaint - filed by Vectura Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Proposed Order )(Farnan, Kelly) Modified on 11/10/2016 (nms). (Entered: 11/10/2016) | |||
| 2016-11-10 | 15 | 0 | ORDER Granting 14 Unopposed Motion For Leave to File a Second Amended Complaint, filed by Vectura Limited. Signed by Judge Richard G. Andrews on 11/10/2016. (nms) (Entered: 11/10/2016) | |||
| 2016-11-10 | 16 | 0 | SECOND AMENDED COMPLAINT For Patent Infringement against Glaxo Group Limited, GlaxoSmithKline LLC- filed by Vectura Limited.(nms) (Entered: 11/10/2016) | |||
| 2016-12-01 | 17 | 0 | ANSWER to 16 Amended Complaint with Jury Demand, by Glaxo Group Limited, GlaxoSmithKline LLC.(Blumenfeld, Jack) Modified on 12/2/2016 (nms). (Entered: 12/01/2016) | |||
| 2016-12-01 | 18 | 0 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent GlaxoSmithKline plc. for Glaxo Group Limited filed by Glaxo Group Limited. (Blumenfeld, Jack) (Entered: 12/01/2016) | |||
| 2016-12-06 | 19 | 0 | Order Setting Rule 16(b) Conference: A Scheduling Conference is set for 1/4/2017, at 11:00 AM in Chambers before Judge Richard G. Andrews (see Order for further details). Signed by Judge Richard G. Andrews on 12/5/2016. (nms) (Entered: 12/06/2016) | |||
| 2016-12-16 | 20 | 0 | MOTION for Pro Hac Vice Appearance of Attorney Michael P. McGraw - filed by Vectura Limited. (Farnan, Kelly) (Entered: 12/16/2016) | |||
| 2016-12-16 | 21 | 0 | MOTION to Strike Defendants' Sixth Affirmative Defense Under Federal Rule of Civil Procedure 12(f) - filed by Vectura Limited. (Attachments: # 1 Proposed Order)(Farnan, Kelly) Modified on 12/19/2016 (nms). (Entered: 12/16/2016) | |||
| 2016-12-16 | 22 | 0 | OPENING BRIEF in Support re 21 MOTION to Strike Defendants' Sixth Affirmative Defense Under Federal Rule of Civil Procedure 12(f), filed by Vectura Limited.Answering Brief/Response due date per Local Rules is 12/30/2016. (Farnan, Kelly) Modified on 12/19/2016 (nms). (Entered: 12/16/2016) | |||
| 2016-12-28 | 23 | 0 | NOTICE OF SERVICE of (1) First Set of Interrogatories to Vectura; and (2) First Set of Requests for Production to Vectura filed by Glaxo Group Limited, GlaxoSmithKline LLC.(Blumenfeld, Jack) (Entered: 12/28/2016) | |||
| 2016-12-29 | 24 | 0 | PROPOSED Scheduling Order, by Vectura Limited. (Farnan, Kelly) Modified on 12/29/2016 (nms). (Entered: 12/29/2016) | |||
| 2016-12-30 | 25 | 0 | AMENDED ANSWER to 16 Amended Complaint by Glaxo Group Limited, GlaxoSmithKline LLC. (Blumenfeld, Jack) (Entered: 12/30/2016) | |||
| 2017-01-09 | 26 | 0 | PROPOSED Scheduling Order, by Vectura Limited. (Farnan, Kelly) Modified on 1/9/2017 (nms). (Entered: 01/09/2017) | |||
| 2017-01-09 | 27 | 0 | SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Joinder of Parties due by 9/5/2017. Amended Pleadings due by 9/5/2017. Fact Discovery completed by 2/12/2018. Dispositive Motions due by 8/3/2018. Answering Brief due 8/31/2018. Reply Brief due 9/14/2018. Joint Claim Construction Brief due by 12/8/2017. A Markman Hearing is set for 1/3/2018, at 9:00 AM in Courtroom 6A before Judge Richard G. Andrews. A Pretrial Conference is set for 12/7/2018, at 10:00 AM in Courtroom 6A before Judge Richard G. Andrews. A five-day Jury Trial is set for 12/17/2018, at 9:30 AM in Courtroom 6A before Judge Richard G. Andrews (see Order for further details). Signed by Judge Richard G. Andrews on 1/9/2017. (nms) (Entered: 01/09/2017) | 2017-03-27 18:17:38 | 273d4102e4932f8966a8715b0704a23f23b20bd1 | |
| 2017-01-09 | 28 | 0 | ORDER Setting Teleconference: Plaintiff's counsel to initiate the call. A Telephone Conference is set for 1/17/2017 at 11:00 AM Eastern Time before Judge Mary Pat Thynge to discuss ADR. Signed by Judge Mary Pat Thynge on 1/9/17. (cak) (Entered: 01/09/2017) | |||
| 2017-01-20 | 29 | 0 | NOTICE OF SERVICE of Vecturas First Set of Requests for Production of Documents and Things to Glaxo and Vecturas First Set of Interrogatories to Glaxo filed by Vectura Limited.(Farnan, Kelly) (Entered: 01/20/2017) | |||
| 2017-01-25 | 30 | 0 | ORDER Setting Mediation Conferences: A Mediation Conference is set for 6/28/2017 at 10:00 AM in Courtroom 2B before Judge Mary Pat Thynge. SEE ORDER FOR DETAILS. Signed by Judge Mary Pat Thynge on 1/25/17. (cak) (Entered: 01/25/2017) | |||
| 2017-01-27 | 31 | 0 | NOTICE OF SERVICE of Vectura's Objections and Responses to Glaxo's First Set of Requests for Production (Nos. 1-60) and Vectura's Objections and Responses to Glaxo's First Set of Interrogatories (Nos. 1-9) filed by Vectura Limited.(Haynes, Christine) (Entered: 01/27/2017) | |||
| 2017-02-02 | 32 | 0 | STIPULATION TO EXTEND TIME to submit proposed Protective Order to February 10, 2017 - filed by Vectura Limited. (Farnan, Kelly) Modified on 2/2/2017 (nms). (Entered: 02/02/2017) | |||
| 2017-02-03 | 33 | 0 | NOTICE OF SERVICE of (1) Defendants' Initial Disclosures and (2) GSK's Disclosures Pursuant to Paragraph 3 of the District of Delaware Default Standard for Discovery filed by Glaxo Group Limited, GlaxoSmithKline LLC.(Blumenfeld, Jack) (Entered: 02/03/2017) | |||
| 2017-02-03 | 34 | 0 | NOTICE OF SERVICE of (1) Vectura's Rule 26(a)(1) Initial Disclosures; (2) Vectura's Default Standard Paragraph 3 Initial Disclosures; and (3) Vectura's Identification of Accused Products and Asserted Patents filed by Vectura Limited.(Haynes, Christine) (Entered: 02/03/2017) | |||
| 2017-02-10 | 35 | 0 | STIPULATION TO EXTEND TIME Proposed Protective Order to through and including February 17, 2017 - filed by Vectura Limited. (Farnan, Kelly) (Entered: 02/10/2017) | |||
| 2017-02-16 | 36 | 0 | STIPULATION TO EXTEND TIME to submit Proposed Protective Order to February 24, 2017 - filed by Vectura Limited. (Farnan, Kelly) Modified on 2/21/2017 (nms). (Entered: 02/16/2017) | |||
| 2017-02-21 | 37 | 0 | NOTICE OF SERVICE of 1) Defendant GlaxoSmithKline LLC and Glaxo Group Limited's Objections and Responses to Plaintiff Vectura's First Set of Interrogatories (Nos 1-10) and 2) GlaxoSmithKline LLC and Glaxo Group Ltd.'s Objections and Responses to Vectura's First Set of Requests for Production of Documents and Things to Glaxo filed by Glaxo Group Limited, GlaxoSmithKline LLC.(Blumenfeld, Jack) (Entered: 02/21/2017) | |||
| 2017-02-23 | 38 | 0 | PROPOSED Protective Order, by Vectura Limited. (Farnan, Kelly) Modified on 2/23/2017 (nms). (Entered: 02/23/2017) | |||
| 2017-02-24 | 39 | 0 | SO ORDERED Approving 38 Stipulated Protective Order. Signed by Judge Richard G. Andrews on 2/23/2017. (nms) (Entered: 02/24/2017) |